Leheny A. Rachel reported grant involving 186,729 derivative units of CalciMedica, Inc. at $0.00 for $0 on Aug 19, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
CHIEF EXECUTIVE OFFICER
CHIEF EXECUTIVE OFFICER
Filed Aug 21, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
186,729Warrant
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
186,729Direct
Trade date
Aug 19, 2026Grant
Filed
Aug 21, 2026, 6:35 PM ET2-day reporting delay
Accession
0001484729-26-000005Code A · Transaction 31031
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

CALC price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
CALC · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +23%1w ago +7%1d ago +11%
Returns since7d −19%30d +237%90d180d1y

Footnotes in full

F1: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. F2: The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%. F3: The warrant may be exercised on or after August 19, 2026, and on or prior to June 25, 2031; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%.